In short
REGN7508 is an experimental drug currently being studied in clinical trials for its potential to prevent blood clots in various medical situations. These trials are investigating the drug's effectiveness, safety, and how it works in the body. The studies focus on different scenarios, including knee replacement surgery, catheter placement, and its use in combination with other medications. Researchers are also examining how the drug compares to existing treatments and its effects on healthy volunteers.
At a glance
- Drug Name
- REGN7508
- Drug Type
- Factor XI Monoclonal Antibody
- Primary Purpose
- Prevention of Venous Thromboembolism (VTE)
- Administration
- Single intravenous (IV) dose or subcutaneous (SC) injection
- Trial Phases
- Phase 1 and Phase 2
- Study Populations
- Knee replacement patients, PICC line patients, healthy volunteers
- Key Outcomes Measured
- VTE incidence, bleeding events, drug concentrations, antibody formation
- Comparators
- Enoxaparin, Rivaroxaban, Placebo
- Safety Assessments
- Adverse events, bleeding incidents, changes in blood clotting tests
What is REGN7508?
REGN7508 is an experimental drug currently being studied for its potential to prevent blood clots. It belongs to a class of medications called monoclonal antibodies, which are laboratory-made proteins designed to target specific substances in the body. In this case, REGN7508 targets a protein called Factor XI, which plays a role in blood clotting.
How Does REGN7508 Work?
REGN7508 works by targeting and inhibiting Factor XI, a protein involved in the blood clotting process. By blocking this protein, REGN7508 may help prevent the formation of unwanted blood clots. This mechanism of action is different from traditional blood thinners, which often target other parts of the clotting process.
What Conditions Does REGN7508 Treat?
REGN7508 is being studied for its potential to prevent a condition called venous thromboembolism (VTE). VTE is a term that includes two related conditions:
- Deep Vein Thrombosis (DVT): This occurs when a blood clot forms in a deep vein, usually in the leg.
- Pulmonary Embolism (PE): This happens when a blood clot travels to the lungs, potentially blocking blood flow.
Specifically, REGN7508 is being investigated for preventing VTE in the following situations:
- After knee replacement surgery
- In patients with a peripherally inserted central catheter (PICC), which is a type of intravenous line
How is REGN7508 Administered?
REGN7508 is being tested in two main forms of administration:
- Intravenous (IV) injection: This involves giving the drug directly into a vein. In most trials, REGN7508 is administered as a single IV dose.
- Subcutaneous (SC) injection: This involves injecting the drug under the skin. Some trials are exploring this method of administration.
Current Clinical Trials
REGN7508 is currently being studied in several clinical trials:
- ROXI-VTE II Trial: This study is testing REGN7508 for preventing blood clots after knee replacement surgery.
- ROXI-CATH Trial: This trial is investigating REGN7508 for preventing blood clots in patients with a PICC line.
- Gastrointestinal Blood Loss Study: This trial is comparing REGN7508 to other blood thinners to see if it causes less bleeding in the digestive system.
- Phase 1 Safety Study: This early-stage trial is testing different doses of REGN7508 to evaluate its safety and how it works in the body.
Safety and Side Effects
As REGN7508 is still in the experimental stage, its full safety profile is not yet known. The ongoing clinical trials are designed to assess the drug's safety and potential side effects. Some key points being studied include:
- Bleeding risk: Researchers are monitoring for major bleeding and clinically relevant non-major bleeding.
- Changes in blood clotting tests: The trials are measuring changes in tests like activated partial thromboplastin time (aPTT) and prothrombin time (PT), which indicate how quickly blood clots.
- Immune system response: Researchers are checking if the body develops antibodies against REGN7508, which could affect its effectiveness or safety.
Future Prospects
If the ongoing clinical trials show positive results, REGN7508 could potentially offer a new option for preventing blood clots in various medical situations. Its unique mechanism of action, targeting Factor XI, might provide benefits over existing blood thinners, such as potentially causing less bleeding in the digestive system.
However, it's important to remember that REGN7508 is still in the experimental stage. More research is needed to fully understand its effectiveness and safety before it can be considered for approval as a medication.